News

2026

February 12, 2026
ImmuneSensor Therapeutics Doses First Patient with Aicardi Goutières Syndrome (AGS) in Phase 1b Clinical Study of cGAS inhibitor, IMSB301 

2024

November 20, 2024
ImmuneSensor Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA for cGAS Inhibitor Drug Candidate, IMSB301, for the Treatment of Aicardi Goutières Syndrome (AGS)

October 8, 2024
ImmuneSensor Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead cGAS Inhibitor Drug Candidate, IMSB301 

September 17, 2024
ImmuneSensor Therapeutics Granted New U.S. Patent for its Oral cGAS Inhibitors 

September 16, 2024
ImmuneSensor Therapeutics to Participate in the UBS 2024 Virtual Biotechnology Private Company Symposium

August 19, 2024
ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301 

May 1, 2024
ImmuneSensor Therapeutics Appoints Veteran Biopharma Executive, Thomas W. Dubensky, Jr., Ph.D., as Chief Executive Officer